Swiftmerge Acquisition Corp. (IVCP)
| Previous Close | 10.64 |
| Open | 10.64 |
| Bid | 10.32 x 800 |
| Ask | 10.64 x 1400 |
| Day's Range | 10.64 - 10.64 |
| 52 Week Range | 9.84 - 11.85 |
| Volume | |
| Avg. Volume | 1,157 |
| Market Cap | 83.757M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 106.40 |
| EPS (TTM) | 0.10 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireHDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.
NEW YORK & VERO BEACH, Fla., August 11, 2023--HDL Therapeutics, Inc. ("HDL Therapeutics"), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2™ System) for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia (HoFH), has signed a definitive merger agreement with Swiftmerge Acquisition Corp. (NASDAQ: IVCP) ("Swiftmerge"), a special purpose acquisition company with a disruptive consumer
Simply Wall St.Institutional investors own a significant stake of 36% in Swiftmerge Acquisition Corp. (NASDAQ:IVCP)
Key Insights Significantly high institutional ownership implies Swiftmerge Acquisition's stock price is sensitive to...
Business WireHDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination With $225 Million Swiftmerge (NASDAQ: IVCP) With Goal to Transform Cardiovascular Disease Treatment
NEW YORK & VERO BEACH, Fla., April 24, 2023--NASDAQ IVCP Swiftmerge Acquisition Corp ("Swiftmerge"), a $225 million innovative healthcare investment corporation and a special purpose acquisition company, announced today the signing of a non-binding letter of intent ("LOI") for a business combination with HDL Therapeutics Inc. ("HDL Therapeutics"), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy for reducing coronary atheroma in homozygous familial hy
